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TCT-635
Cost Effectiveness Of Everolimus-Eluting Stents Compared To First
Generation Drug-Eluting Stents In Contemporary Clinical Practice
Robert Applegate1, Matthew Sacrinty1, Sanjay Gandhi1, Michael Kutcher1,
Renato Santos1, Timothy Smith1, William Little1
1Wake Forest School of Medicine, Winston-Salem, NC
Background: Everolimus-eluting stents (EES) reduce adverse clinical outcomes com-
pared to first generation drug-eluting stents (DES) and cost less. Whether EES demon-
strate cost-effectiveness compared to DES within high risk patient subgroups is uncertain.
Methods: Percutaneous coronary intervention with EES (n1,003) and 1st generation
DES (n992) were performed at a single center (Wake Forest Baptist Medical Center)
between January 2007 and December 2010. One-year target lesion revascularization
(TLR) incidence and costs in 2010 dollars were prospectively evaluated and compared
within patient subgroups. Follow-up was 94% for both groups.
Results: Overall baseline characteristics were similar, except for higher use of EES for
ST-elevation myocardial infarction. Clopidogrel use at 1 year was 88% EES vs. 91% DES
(p0.02). Overall, EES was associated with 1.1 less TLR events per 100 patients
compared to DES. Aggregate 1-year costs were $765 less ($1,293 less to $197 less) with
EES (p0.005). EES demonstrated economic dominance (lower costs and TLR inci-
dence) compared to DES in all patient subgroups (see Table).
Cost effectiveness results for patient subgroups
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<$10,000
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C/E
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<$50,000
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Cost with Cost with Avoided
$/TLR
Avoided
TLR
Avoided,
QALY
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Subgroup EES, $ DES, $ DES, $
per 100
pts with EES %*
$/QALY
Gained %*
All patients
(N1995)
5172 5937 765 1.1 Dominant 98.6% Dominant 95.5%
Males
(n1399)
4997 5942 945 2.4 Dominant 99.2% Dominant 97.7%
Females
(n596)
5625 5927 303 0.6 Dominant 60.2% Dominant 47.4%
Age 75 y
(n356)
4598 6020 1421 4.1 Dominant 99.0% Dominant 98.2%
Age 75 y
(n1639)
5288 5918 630 1.3 Dominant 91.0% Dominant 81.7%
Diabetics
(n655)
5462 6673 1211 3.6 Dominant 97.7% Dominant 94.3%
Non-
diabetics
(n1340)
5032 5574 542 0.9 Dominant 89.8% Dominant 80.1%
ST-
elevation
MI
(n419)
4776 5303 527 0.1 Dominant 45.0% Dominant 57.6%
Non-ST-
elevation
ACS
(n1197)
5221 6065 844 2.5 Dominant 98.5% Dominant 93.6%
Off-label
indications
(n1607)
5388 6218 830 2.2 Dominant 98.4% Dominant 95.9%
On-label
indications
(n388)
4343 4681 338 0.3 Dominant 55.1% Dominant 49.7%
*Percentages based on 1,000 bootstrap resamplings. ACS indicates acute coronary syndrome; MI,
myocardial infarction; QALY, quality adjusted life year; TLR, target lesion revascularization.
Conclusions: In this prospective observational registry EES was economically dominant
compared to 1st generation DES in a variety of patient subgroups, including PCI for acute
coronary syndrome and off-label indications.
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Final Three Year Results Following Resolute Zotarolimus-Eluting Stent
Implantation in the RESOLUTE International Trial
Franz-Josef Neumann1, Petr Widimsky2, Jorge Belardi3
1Universitäts-Herzzentrum Freiburg - Bad Krozingen, Bad Krozingen, Germany,
2Charles University, Prague, Czech Republic, 3Instituto Cardiovascular de Buenos
Aires, Buenos Aires, Argentina
Background: The RESOLUTE International (R-INT) trial has demonstrated the safety
and effectiveness of the Resolute zotarolimus-eluting stent (R-ZES) through 2 years in a
real-world population of patients with coronary artery disease requiring percutaneous
coronary intervention (PCI). Concerns regarding long-term safety of drug-eluting stents,
particularly in complex patients and lesions, require ongoing follow-up of clinical trials to
confirm safety and effectiveness.
Methods: The R-INT observational trial prospectively enrolled 2349 patients at centers
across Europe, Argentina, India, and South Africa to undergo PCI using the R-ZES.
Minimal exclusion criteria assured a broad representation of real-world clinical practice.
The primary endpoint was a composite of cardiac death and target-vessel myocardial
infarction (CD/TV-MI). A key secondary endpoint was ARC definite and probable stent
thrombosis. Dual antiplatelet therapy with aspirin and clopidogrel was recommended for
6 months and was prescribed thereafter at operator’s discretion. Death, TV-MI, stent
thrombosis, and target vessel revascularization (TVR) events were adjudicated using the
same definitions and criteria as employed in the Global RESOLUTE Clinical Program.
Results: Two year follow-up was available for 2296 (97.7%) of patients enrolled.
Baseline characteristics include 78% males, mean age of 63.5 years, with 20% presenting
with acute MI and 26.1% with unstable angina; 30.5% of patients had diabetes mellitus.
Two-thirds of the patients were considered complex based on clinical and lesion
characteristics. At 2 years 43.9% of patients were receiving dual antiplatelet therapy. Two
year clinical outcomes include 5.9% CD/TV-MI, 4.5% death, 4.9% target lesion
revascularization, and 6.3% TVR. Very late definite and probable stent thrombosis was
0.1% for the period between 1to 2 years.
Conclusions: At 2 years after R-ZES implantation there is a very low rate of stent
thrombosis and clinical event rates are consistent with 2 year results in 1121 patients
treated with a R-ZES in the RESOLUTE All Comers trial. The final 3 year clinical
follow-up of this large, observational study will be reported.
TCT-637
A Novel Bioactive and Coating-Free Stent Surface Exhibits a Reduction in
Neointimal Hyperplasia by Decreasing Platelet Aggregation and Promoting
Endothelialization
Lynn Bailey1, Adam Groothuis1, Arik Zucker2, Stefano Buzzi2, Armin Mäder2,
Algirdas Ziogas3, Vincent Milleret3, Martin Ehrbar3, Elazer Edelman4
1CBSET, Inc., Lexington, MA, 2Qvanteq AG, Zurich, Switzerland, 3University
Hospital Zurich, Zurich, Switzerland, 4Harvard-MIT Biomedical Engineering
Center, Cambridge, Massachusetts
Background: Qvanteq has applied its novel coating-free bioactive surface technology
onto bare metal stents (BMS).
Methods: In-Vivo: Integrity BMS, Qvanteq-treated Integrity stents (QBM), and Resolute
DES were randomly implanted in a swine coronary artery model up to 90d with
angiographic and histopathological assessments. In-Vitro: treated (QBM) and untreated
CoCr disks were incubated with heparinized human blood for 2 hrs and the adherent blood
components were investigated by immunofluorescence microscopy or SEM. Proliferation
assays were performed using human aortic endothelial cells for up to 96 hrs.
Results: In-Vivo: Quantitative angiography demonstrated a reduction (p0.05) of late
lumen loss and percent stenosis in QBM compared to BMS at 30d and DES at 30 and 90d.
Neointimal area was decreased (p0.05) in QBM compared to BMS and DES. Light
microscopy showed vascular injury, inflammation, and adventitial fibrosis of the QBM
was reduced (p0.05) compared to DES at 30d. Endothelialization was complete in the
QBM and BMS groups and near complete in the DES group. Analogous results were
obtained with treated Multi-Link and Omega stents compared to their untreated BMS and
DES counterparts. In-Vitro: A 10-fold decrease in platelet adhesion and a 5-fold increase
in neutrophil recruitment were observed on the QBM surface compared to the untreated
surface. Proliferative endothelial cell assays at 2d were slightly higher for QBM
(85.8%3.2 coverage) compared to untreated surfaces (78.6%11.2). At 4d cell growth
was comparable with confluent cell coverage on both surfaces (95% coverage).
Conclusions: The QBM surface significantly reduced neointimal hyperplasia in swine
coronaries compared to both BMS and DES, independently from stent design and/or
alloy, without adverse vascular healing effects. In-Vitro data indicate that those results
may be related to a significant reduction of adherent platelets combined with enhanced
neutrophil adhesion, which promote reendothelialization and decrease neointimal hyper-
plasia by locally regulating acute inflammatory response and endothelial recovery.
Therefore, this novel approach may be an effective alternative to DES in reducing clinical
in-stent restenosis.
TCT-638
Late Catch-up Restenosis of Drug Eluting Stents: Evidence from Comparison
with Bare Metal Stents in Japanese CAD Patients
Yuki Horita1, Masatoshi Ikeda1, Isao Inoki2, Masanobu Namura1, Kenji Sakata1,
Hedenobu Terai3
1Kanazawa Cardiovascular Hospital, Kanazawa City, Ishikawa Prefecture,
2Kanazawa Cardiovascyular Hospital, Kanazawa City, Ishikawa Prefecture,
3Kanazawa Cardiovascular Hospital, Kanazawa city, Ishikawa Prefecture
Background: Although incidence of initial restenosis in coronary stenting lesions was
dramatically decreased by use of drug-eluting stent (DES), few data exist regarding late
catch-up restenosis of DES during long term follow-up in Japanese patients. Therefore,
we clarified the efficacy of DES for restenosis in the initial and late catch-up in
comparison with those of bare metal stent (BMS).
Methods: We analyzed 1478 lesions of BMS and 2959 of DES. DESs consisted of the
2091 sirolimus (SES; Cypher & Cypher-Select), 357 paclitaxel (PES; Taxus & Taxus-
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liberte), 90 zotarolimus (ZES; Endeavor) and 421 everolimus eluting stents (EES;
Xience-V & Promus). Initial follow-up angiography was performed at 8 months after
stenting in all patients, and long-term follow-up angiography at 2 years was performed in
patients not exhibiting initial restenosis.
Results: The initial restenosis was 23.3% for BMS, 6.7 for SES, 14.8 for PES, 13.3 for
ZES and 6.7 for EES. Thus, the restenosis rate of BMS was significantly greater than that
in DESs (p0.0001). Interestingly, the initial restenosis of SES and EES were smaller
than those of other DESs. In contrast, long-term restenosis were 7.1% for BMS, 10.7 for
SES, 7.2 for PES, 4.0 for ZES and 2.9 for EES, yielding no significant differences between
them except EES. In late followed study, late loss at 8-months/2-years was 0.76/0.80mm
for BMS, 0.18/0.48 for SES, 0.40/0.49 for PES, 0.60/0.43 for ZES and 0.23/0.32 for EES.
The serial change of late loss in SES was significantly increased and this increase affected
the deterioration of late restenosis in SES.
Conclusions: These results demonstrate that in comparison with BMS, stent-related late
restenosis could not be improved by SES, PES and ZES, probably due to late catch-up
phenomenon associated with inflammation-related neo-atheroslcerosis. But EES could
improve late-catch-up restenosis. We suggest careful long term follow-up of patients who
had DES implation even without intial restenosis.
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Two Year Outcomes Following Implantation of the Resolute Zotarolimus-
eluting Stent in Vessels <2.5 mm Diameter
Ronald Caputo1, Martin Leon2, Patrick Serruys3, Franz-Josef Neumann4,
Alan Yeung5, Stephan Windecker6, Jorge Belardi7, Sigmund Silber8, Ian Meredith9,
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Germany, 5Stanford University School of Medicine, Stanford, USA, 6Bern
University Hospital, Bern, Switzerland, 7Instituto Cardiovascular de Buenos Aires,
Buenos Aires, Argentina, 8Univ. of Munich, Munich, Germany, 9Monash
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Background: Compared to larger vessels percutaneous coronary intervention (PCI) of
small vessel coronary artery disease presents technical challenges and a greater risk for
restenosis, stent thrombosis, and major adverse cardiac events. The long term safety and
effectiveness of drug-eluting stents for small vessel lesions therefore remains a concern.
Methods: Patients with a broad range of clinical and lesion characteristics undergoing
PCI with a Resolute zotarolimus-eluting stent (R-ZES) in small vessels (reference vessel
diameter [RVD] 2.5 mm) were pooled from 5 trials: RESOLUTE All Comers,:
RESOLUTE first-in-human, RESOLUTE International, RESOLUTE Japan, and RESO-
LUTE US. Dual antiplatelet therapy was prescribed for 6 months and at operator
discretion thereafter. Safety and effectiveness endpoints; target lesion failure (TLF;
composite of cardiac death [CD], target vessel myocardial infarction [TVMI], or
clinically-driven target lesion revascularization [TLR]), CD, TVMI, CD or TVMI, TLR,
and definite or probable stent thrombosis (ST) were compared between patients with small
and large vessels (RVD 2.5 mm) after propensity score adjustment for differences in
baseline characteristics.
Results: There were 1956 patients (38.1%) with a RVD 2.5 mm and 3174 patients
(61.9%) with RVD 2.5 mm. Most baseline characteristics were significantly different
between the 2 groups; small vessel patients were older with a higher proportion of females
and had higher rates of diabetes, prior PCI, hypertension, hyperlipidemia, and multivessel
disease.
Two Year Rates of Clinical Events
RVD<2.5
mm
RVD
<2.5 mm
Adjusted
P-value
TLF 10.1% 8.7% 0.535
Cardiac death 2.0% 2.4% 0.668
TVMI 3.9% 3.2% 0.380
CD or TVMI 5.7% 5.2% 0.488
Clinically-driven TLR 5.3% 4.4% 0.341
ST (def/prob) 0.8% 1.0% 0.288
- early (30 d) 0.5% 0.6% 0.550
- late (31-360 d) 0.3% 0.2% 0.360
- very late (360 d) 0.1% 0.2% 0.283
Conclusions: After adjustment for differences in baseline characteristics there are no
significant differences in safety and effectiveness outcomes to 2 years between patients
with large and small vessel disease. The rates of CD, TVMI and ST provide evidence for
the long-term safety of R-ZES in patients regardless of RVD.
TCT-640
Very Late Stent Thrombosis is Associated with Lower Mortality than Early
Stent Thrombosis: A Report from the VHA CART Program
Ehrin Armstrong1, Thomas Maddox2, Evan Carey2, Gary Grunwald2,
Kendrick Shunk3
1UC Davis, Sacramento, CA, 2University of Colorado, Denver, CO, 3San
Francisco VA Medical Center, San Francisco, CA
Background: Recent data suggest that late or very late stent thrombosis (ST) is
associated with lower in-hospital mortality than early ST, but data on longer-term
outcomes is lacking.
Methods: Data from the VHA Cardiovascular Assessment, Reporting, and Tracking
(CART) Program was used to identify all presentations of angiographic ST with known
timing between 2006-2011 at 76 VA hospitals. In accord with the Academic Research
Consortium (ARC) standards, cases occurring  30 days after stent implantation were
defined as early; 31-365 days as late; and  365 days as very late. Cox-proportional
hazard regression modeling with backwards covariate selection was used to describe
differences in mortality rates after ST.
Results: A total of 448 patients with ST and known time from initial stent implantation
were identified. The cohort consisted of 124 (28%), 96 (21%), and 228 (51%) patients
with early, late and very late ST, respectively. Late and very late ST were associated with
lower crude mortality than early ST at both 30-days and 90-days (Figure). On multivariate
modeling, patients with very late ST had significantly lower 30-day mortality (HR 0.3,
[95% CI 0.13-0.68]) when compared to patients with early ST. Similar trends were also
observed for late ST compared to early ST.
Conclusions: Long term mortality risk following an angiographic ST presentation differs
as a function of time from index PCI to ST, potentially reflecting the differing mechanisms
of ST that predominate at different timeframes. Specifically, ARC very late ST is
associated with lower mortality at 30 days when compared to early ST.
TCT-641
The effect of balloon angioplasty compared with drug-eluting stent (DES)
implantation for the treatment of DES in-stent restenosis.
taku ichihashi1, Yasushi Asakura1, Maoto Habara1, Syuichi ishiduka1,
Tsuyoshi Ito2, Masashi Kimura1, Yoshihisa Kinoshita2, Atsuko kodama1,
Tairo Kurita1, Tetsuo Matsubara1, Kenya Nasu3, Takahiko Suzuki1,
Tomohiko Teramoto1, Mitsuyasu Terashima1, Etsuo Tsuchikane1, Daisuke Yokota1
1Toyohashi Heart Center, Toyohashi, Japan, 2Toyohashi Heart Center, Toyohashi,
Aichi, 3Toyohashi Heart Center, Toyohashi, Aichi, Japan
Background: There are no observational studies directly comparing the safety and
efficacy of balloon angioplasty (POBA) versus DES for treatment of DES in-stent
restenosis (ISR).
Methods: We examined data on all patients who underwent percutaneous coronary
intervention (PCI) for ISR at Toyohashi Heart Center between 01/2004 and 05/2012. We
compared the efficacy of DES to balloon angioplasty for treating DES ISR.
Results: Of the 9126 patients who underwent PCI treated with DES over 8 years, 512 had
DES ISR and met our study criteria. Of the 353 patients with DES ISR, were treated with
balloon angioplasty and 129 with DES. At 1-year angiographic follow-up (follow-up rate:
73%), in-stent restenosis was observed in 117 cases in the POBA group and 28 cases in
the DES group (45% vs. 30%; P  0.017). In a comparison between treatments using a
cutting balloon vs. a conventional balloon, there was no significant difference observed in
the rate of angiographic restenosis.
Conclusions: In our analysis of patients with DES ISR, DES use was associated with a
significantly lower rate of ISR or TLR when compared to POBA.
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